Monograph Details
|
|
Immune System
> Immunization
|
|
PNEUMOVAX 23 |
| Manufacturer |
|
Merck & Co., Inc. |
| Legal Classification |
|
Rx
|
| Generic Name |
|
Pneumococcal vaccine 25micrograms; each of 23 polysaccharide isolates; inj; contains phenol. |
| Indications |
|
Immunization against pneumococcal disease caused by approximately 85–90% of common U.S. isolates. |
| Adults and Children |
|
<2yrs: not recommended. ≥2yrs: 0.5mL IM or SC once in deltoid muscle or lateral mid-thigh. |
| Contraindications |
|
Not for routine revaccination after previous pneumococcal vaccination in immunocompetent patients. Within 14 days of immunosuppressive therapy. |
| Precautions |
|
Severe cardiac or pulmonary disease where a systemic reaction would pose a significant risk. May defer in acute febrile respiratory illness or other active infection. Do not discontinue antipneumococcal prophylactic antibiotic therapy. Have epinephrine inj (1:1000) available. Pregnancy (Cat.C). Nursing mothers. |
| Adverse Reactions |
|
Inj site reactions, low grade fever. |
| How Supplied |
Multidose vials—1,10
Single-dose vials—10 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
